While standard models suffer from context rot as data grows, MIT’s new Recursive Language Model (RLM) framework treats ...

Nature is its own most incorrigible plagiarist; echoes of the same aesthetic motifs show up in all kinds of places and all kinds of scales. Here, the finned texture resembles the underside of a ...

When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...

A small-scale artificial-intelligence model that learns from only a limited pool of data is exciting researchers for its potential to boost reasoning abilities. The model, known as Tiny Recursive ...

Management believes it can drastically cut down the time and cost to bring drugs to market. The company is involved with multiple clinical trials, but none of them are in late stages just yet. Its ...

Recursion Pharmaceuticals remains a high-cash-burn, premium-valued biotech with unproven clinical success despite a recent 47% rally. RXRX's next 18 months are catalyst-rich, but key pipeline assets ...

Rallybio has swerved away from its Recursion Pharmaceuticals pact, accepting $7.5 million upfront for its share of a preclinical program to extend its cash runway to mid-2027. Exscientia, now part of ...

IMDb.com, Inc. takes no responsibility for the content or accuracy of the above news articles, Tweets, or blog posts. This content is published for the entertainment of our users only. The news ...